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Use of cytokines as biomarkers for disease is getting more widespread. Cytokines are conveniently determined by immunoassay,
but interference from present antibodies is known to cause problems. In rheumatoid arthritis (RA), interference of rheumatoid
factor (RF) may be problematic. RF covers a group of autoantibodies from immunoglobulin subclasses and is present in 65–80%
of RA patients. Partly removal of RF is possible by precipitation. This study aims at determining the eﬀects of presence of RF in
blood and synovial ﬂuid on cytokine measurements in samples from RA patients and ﬁnding possible solutions for recognized
problems. IL-1β, IL-4, IL-6, and IL-8 were determined with multiplex immunoassays (MIA) in samples from RA patients prior to
and after polyethylene glycol (PEG 6000) precipitation. Presence of RF does interfere with MIA. PEG 6000 precipitation abolishes
this RF interference. We recommend PEG precipitation for all immunoassay measurements of plasma samples from RA patients.
1.Introduction
Several autoantibodies are described in plasma and synovial
ﬂuid from rheumatoid arthritis (RA) patients [1]. Two of
these, rheumatoid factor (RF) and anticitrullinated protein
antibodies (anti-CCP), are used in routine diagnostic work.
RF was ﬁrst described by Waaler around 1940 [2] and is
not a clearly deﬁned molecule but a combination of auto-
antibodies of the types IgM, IgG, IgA, IgD, or IgE [1, 3–5].
RFs are deﬁned as Ig autoantibodies which bind via variable
sequencesoftheirFabregiontotheFcregionofanIgG[3,6].
RFs show high reactivity with the IgG type 1, 2, and 4, but
less with type 3, indicating that the antigen speciﬁcity of IgG
is not relevant, but the type of Fc region is [6, 7]. It is usually
IgM and/or IgG, which are the most abundant, and IgM
concentration alone, or the concentration of both together,
is expressed as the RF concentration when measured in a
clinical setting [8]. RF is found in plasma from 65 to 80% of
subjects with RA and some other connective tissue diseases
[4, 9, 10], as well as in a condition like pneumonia [11],
and RF interference is therefore a very real problem when
measuringsamplesfromRApatients.IgMRFinRAismainly
of the soluble pentameric form [3, 4, 6] which shows high
aﬃnity to IgG binding.
Apart from RF and anti-CCP, there are autoantibodies
which react with antigens from other species, but with
weak avidity. Human antimouse antibody (HAMA), mainly
IgG, is the most prevalent [12]. “Heterophilic antibodies”,
among these RF, are well-known sources of interference in
immunoassay of proteins in samples from human plasma,
cerebrospinal ﬂuid, or synovial ﬂuid [13–18], but interfer-
ence from most autoantibodies can easily be counteracted
for, while IgM in its pentameric form is particularly reactive
due to its polyvalence [12].
Interference from heterophilic antibodies may occur in
all designs of immunoassays, but the immunometric type is
known to be most exposed to this [19]. This is due to the
heterophilic antibodies’ ability to bridge between the capture
and the detection antibodies in the immunometric setup,
and thereby create a false signal.2 Arthritis
Since multiplex immunoassay (MIA) and two-site
enzyme-linked immunosorbent assay (ELISA), the most
commonly applied methods for quantitative determination
of cytokines, are both immunometric and mainly using
detection antibodies of the IgG type, interference from RF
must be considered to be a potential serious problem when
measuring samples from RA patients.
With the growing understanding of the immunological
processes involved in RA, determination of cytokine proﬁles
as biomarkers is getting more widespread and has been
proposed for early detection of RA [20], diﬀerential diag-
nosing [21, 22], and monitoring of eﬀect of treatment with
cytokine-binding antibody preparations [15]. As a precau-
tion against part of the heterophilic antibodies, common
practice is to add various cocktails of mouse, calf, goat,
and rabbit serum to assay diluents for immunoassay. The
major problem left is then interference of RF in RF-positive
patient samples with a high concentration of RF [4, 9, 23]. A
suggested solution is to precipitate at least part of RF with
polyethylene glycol 6000 (PEG 6000) [24–26]. There is a
good reason for this choice, since the main suspected culprit
in the interference of RFs with the IgG antibodies is believed
to be the polyclonal IgM RF, and PEG 6000 will precipitate
these larger complexes but very little of the lower molecular
monomers [25, 27, 28]. Another suggested precipitation
agent is protein L [24], but price in relation to binding
capacity makes use of protein L impossible for clinical tests.
A na t t e m p tt or e m o v eR Fwi t hab l o c kc o p o l ym e ro fe t h y l e n e
and propylene (HeterBlock) and/or protein-L has also been
made [20], but the results were variable and inconclusive.
In the present study, our aim was to determine to
which degree presence and concentration of RF will interfere
with MIA cytokine measurements carried out on plasma
or synovial ﬂuid from patients representing a range of
RF concentrations and to validate sample pretreatment
procedures using PEG 6000 precipitation to reduce possible
interference from RF.
2.MaterialsandMethods
2.1. Patients and Samples. Samples from ten patients from
the Rheumatology Clinic at Frederiksberg Hospital, age
range 35 to 75 years, three men and seven women, all
having active RA and fulﬁlling the ACR-criteria [29], were
included. Five plasma samples were chosen, representing a
range of RF concentrations from 8 to 1141IU/mL, and ﬁve
synovial ﬂuid samples were chosen, representing a range
of RF concentrations from 2 to 189IU/mL. The patients
were part of a group treated with cytokine-binding antibody
preparations. To be classiﬁed as RF-positive means having
a plasma RF concentration above a set deﬁned value, for
example, in Denmark 17IU/mL, hence one of the plasma
samplesusedforthestudywasfromapatientconsideredRF-
negative.
All patients gave informed consent to participate in
the study, which was approved by the Frederiksberg and
Copenhagen Municipalities’ Ethics Committee (no. KF01-
256496).
Blood was drawn into K2EDTA-sprayed Vacutainers (BD
Diagnostics, Franklin Lakes, NJ, USA) and stored directly
at −80◦C. Joint ﬂuid was drawn with a syringe from the
knee joint, immediately transferred to a polypropylene vial,
centrifuged at RCF 500×g, and then the supernatant was
stored at −80◦C.
2.2. Determination of RF. The concentration of RF in the
samples of plasma and synovial ﬂuid, prior to and following
PEG 6000 precipitation, was measured by immunotur-
bidimetrics at the Department of Clinical Biochemistry,
Frederiksberg Hospital. The method used gives the RF con-
centration as the concentration of IgM. A nonprecipitated
and the PEG 6000-precipitated aliquot of each plasma or
synovial ﬂuid sample was measured on the same day.
2.3. Removal of Antibodies by Precipitation with Polyethylene
Glycol 6000 (PEG 6000). Prior to measurements, samples
were thawed at room temperature and mixed. An 800μL
aliquotofthesynovialﬂuidwascentrifugedatRCF16000×g
for 30 minutes, which is our procedure for removal of
ectosomes.
Synovial ﬂuid was treated with hyaluronidase from
bovine testes (Sigma, St. Louis, Mo, USA) 5000, that is, per
mL sample, incubated at room temperature for 10 minutes,
in order to reduce the viscosity.
RFs were removed from samples by PEG precipitation
as described by De Jager et al. [24]. The method is eﬀective
and at the same time gentle to the cytokine analytes: a 30%
solutionofPEG6000(Merck,Darmstadt,Germany)in0.1M
sodium phosphate buﬀer, pH 7.4, was added in volume ratio
1:10, to give a ﬁnal concentration of 3% PEG 6000. Samples
were mixed and left at 4◦Cf o r6 0m i n u t e s ,c e n t r i f u g e da t
RCF 700×g for 45 minutes, and the supernatant was used
for analysis.
2.4. Immunoassay Reagents. T h ep o s s i b l ee ﬀe c to fR Fo n
immunoassays of cytokines was evaluated by analysis in the
following assays, which we have developed and validated
in ELISA and MIA format: interleukins (IL-) IL-1β CptAb
monoclonal, clone 508A 7G8 mouse IgG1, and 508A 4A2
mouse IgG1, DtcAb monoclonal, clone 508A 3H12 mouse
IgG1, CP recombinant human, all from BS; IL-4 CptAb,
DtcAb, CP recombinant human, all from BS; IL-6 CptAb
monoclonal, clone 677B 6A2 mouse IgG1,D t c A bm o n -
oclonal, clone 505E 23C7 mouse IgG1, CP recombinant
human,allfromBS;IL-8(CXCL8)CptAbmonoclonal,clone
893A6G8mouseIgG1,DtcAbmonoclonal, clone790A 28G2
mouse IgG1, CP recombinant human, all from BS (“BS”
is Biosource, Invitrogen Life Technologies, Carlsbad, Calif,
USA).
The above-mentioned capture antibodies were cova-
lently coupled to ﬂuorescent, carboxylated microspheres
(Luminex, Austin, Tex, USA) by the carbodiimide method
a d v i s e di nl i t e r a t u r e[ 30, 31]. The concentrations of cap-
ture antibodies in the coupling step had been titrated in
numerous experiments, to result in a uniform, high density
of capture antibody coupled to all the microspheres in the
suspension, to make a sample of these appear as a narrowArthritis 3
Table 1: RF concentrations in the plasma samples prior to and
following precipitation in patients 1–5 (P1–5). P1 is RF-negative,
the rest are RF-positive.









peak in ﬂow cytometry after reaction with RPE-conjugated
goat antimouse IgG.
2.5. Multiplex Immunoassay Procedure. The assay procedure
had been optimized as to the concentrations of detection
antibodies and the details of incubation times, number of
washes, and assay buﬀer composition, resulting in following
regimen: the capture antibody microspheres were blocked
a n ds t o r e di nap h o s p h a t eb u ﬀered saline pH 7.40 (PBS)
with 1% bovine serum albumin and 0.05% sodium azide.
The density of the suspension of capture beads was adjusted
to 1400 beads for each analyte per 25μL, and this volume
was pipetted into each well of the microtitre plate. This
amount of beads with capture antibody coupled to their
surface had a binding capacity in far excess of the amount
of analyte able to speciﬁcally bind to the capture antibody
concerned.Samplesofplasmaorsynovialﬂuid,insomecases
PEG-precipitated, were diluted 1:4 with an assay diluent
composed of PBS with 0.5% bovine serum albumin, and
25μL of this diluted sample were pipetted onto the inner
wall of each of duplicate wells. The microtitre plates were
covered with adherent foil, centrifuged at RCF 200×gf o r
1 minute to combine sample and capture bead suspension,
and incubated for 90 minutes with agitation at ambient
temperature in the dark. Then 25μL of the solution of the
detection antibodies for all the analytes, dissolved in PBS
with 0.5% bovine serum albumin, were added, the plates
centrifuged at RCF 200×g for 1 minute, incubated for 120
minutes with agitation, and placed in 4◦Cr e f r i g e r a t o ro v e r
the night. The beads were washed with 200μL PBS with
agitation for 5 minutes, centrifugation at RCF 400×gf o r6
minutes, and aspiration of the supernatant by means of a
microtitre plate washer. A diluted solution of streptavidin-
RPE (Molecular Probes, Eugene, Ore, USA) of 20μg/mL in
PBS with 1% BSA of 20μL was added to each well, the
plates gently centrifuged, incubated for 30 minutes with
agitation at ambient temperature in the dark, the beads
washed with 200μL sheath solution for ﬂow cytometry (BD
Biosciences,SanJose,Calif,USA),centrifugedatRCF400×g
for 6 minutes, and the supernatant aspirated. Finally 120μL
sheath solution were added, the beads were suspended by
agitation and analyzed in a FACSArray Bioanalyzer ﬂow
cytometer (Becton Dickinson Immunocytometry Systems,
San Jos´ e, Calif, USA).
Table 2: RF concentrations in synovial ﬂuid prior to and following













SF1 2 1 7
SF2 34 1 85
SF3 29 13 78
SF4 54 15 54
SF5 189 60 400
2.6. Cytokine Spiking of Samples. The plasma or synovial
ﬂuid samples were spiked with the studied cytokines and
added to the assay diluent. This diluent was used for dilution
of samples. The resulting “Addition” samples were a neat
sample, with no cytokines added, and diluted samples with a
composition corresponding to a 1:4 dilution of an authentic
sample with concentrations 3.4pg/mL to 2500pg/mL of
each cytokine, and prepared to give 3-fold steps. In one
experiment, the spiked diluent was added either prior to or
following PEG precipitation, in order to evaluate the extent
of cytokine loss by coprecipitation from the supernatant
layer.
2.7. Data Handling. Bead clusters were separated in far-
red versus red diagrams, gated, and median ﬂuorescence
intensity (MFI) of the reporter in yellow channel recorded.
The data were calculated in the FACS Array and FCAP Array
software.
3. Results
3.1. Samples. Table 1 shows the concentrations of RF of
IgM type in the plasma samples P1–P5 prior to and
following precipitation with PEG 6000. In Denmark, the
deﬁnition of being RF-positive is to have a plasma RF
concentration higher than 17IU/mL. Hence in our material
P1 corresponded to RF negative, and samples P2–P5 to RF-
positive. PEG-precipitation removed around half of the RF
of the IgM type in plasma.
Table 2 shows the RF IgM concentrations in the synovial
ﬂuid samples SF1–SF5 prior to and following PEG 6000
precipitation, which removed between all and two thirds
of the RF of IgM type in this type of sample material.
The concentration of RF in nonprecipitated synovial ﬂuid
in proportion to the RF concentration in plasma from the
same patient at the same time varied signiﬁcantly. SF1 came
from an RF-negative patient while, SF2–SF5 came from RF-
positive patients.
3.2. Interference from RF. Precipitation of RF in plasma
or synovial ﬂuid did change the interaction of a panel of
cytokines with the antibody reagents used in MIA. This
is illustrated by the ratio between the median ﬂuorescence
intensities (MFIs), measured by the ﬂow cytometer, in the4 Arthritis
Table 3: Cytokine concentration in nonprecipitated and PEG-precipitated plasma samples with low RF (P1) and high RF (P4) and synovial
ﬂuid samples with low RF (SF1) and high RF (SF4) as well as sensitivity for the assay and ratio between concentrations in nonprecipitated













P1 369 272 0,737 0/0
P4 290,5 220 0,757 1.5/0
SF1 169 219 1,296 0/0
SF4 259 270 1,042 0/0
IL-4 sensitivity: 27pg/mL
P1 334 271 0,811 0/0
P4 309,8 245 0,791 0.2/0
SF1 336 292 0,869 0/0
SF4 337,6 355 1,052 3.4/0
IL-6 sensitivity: 11.5pg/mL
P1 368 290 0,788 0/0
P4 477,4 290 0,607 2.6/0
SF1 293 289 0,986 43/58
SF4 362 386 1,066 96/115
IL-8 sensitivity: 14.0pg/mL
P1 280 225 0,804 0/0
P4 355,8 275 0,773 9.2/0
SF1 306 296 0,967 54/29
SF4 387 398 1,028 88/42
Table 4: Ratio of cytokine concentrations measured from samples
spiked with cytokine and then PEG-precipitated and samples which
were PEG-precipitated and then spiked with cytokine. Mean ± SD
given.
Analyte Ratio spiked sample precipitated:sample matrix
precipitated, then spiked Mean ± SD
IL-1β 0.94 ± 0.15
IL-4 1.01 ± 0.14
IL-6 0.95 ± 0.16
analysis of the PEG-precipitated and the nonprecipitated
aliquot of the same sample, shown in Figures 1(a) and 1(b)
for IL-1β in plasma and synovial ﬂuid, respectively. IL-1β
was chosen here due to no present baseline concentration
in our samples. Notice that in P5 who had an extreme
concentration of RF, little eﬀect of precipitation of RF was
seen, but the RF concentration was here still two to three
times the RF concentration considered high. Table 3 shows
theconcentrationmeasuredpriortoandfollowingPEG6000
precipitation in plasma for the patient with low RF (P1) and
a patient with high (P4) concentration in the region most
commonly found, as well as the concentration measured
prior to and following PEG 6000 precipitation in SF for the
patient with low RF (SF1) and a patient with high RF (SF4)
concentration. PEG precipitation does not have a great eﬀect
on SF.
3.3. Inﬂuence of PEG Precipitation on Cytokine Concentration.
Loss of sample contents from cytokines by the PEG-
precipitation was evaluated by comparison of the results
from two procedures: (1) samples were spiked with the
cytokinespriortoprecipitationandthenassayed;(2)samples
were precipitated, then spiked and assayed. This was done
for the four cytokines IL-1β, IL-4, and IL-6. The results are
shown in Table 4 giving the ratio between concentrations
measured by method 1 and by method 2 for precipitation.
No signiﬁcant diﬀerence between the cytokine results from
the two procedures was seen for any of the analytes. The
ratio between the two values was in all cases close to
unity, indicating that PEG precipitation does not precipitate
cytokines and therefore does not change the true cytokine
concentrations in plasma and that the apparently high
cytokine concentration seen with RF-positive patients must
be due to interference from RF.
3.4. Interference from Multiplexing. To assure that the inter-
ference of RF seen in MIA measurements was not due to the
MIA setup, nonprecipitated plasma samples were assayed by
multiplex and by singleplex (only capture beads and DtcAb
for one analyte in the same microtiter plate well) for a
selection of cytokines, IL-1β, IL-4, and IL-6. There was no
signiﬁcant diﬀerence in the measured concentrations in the
two setups.
4. Discussion
In the present study, we have shown that RF in the concen-
trations which frequently occur in the plasma of RA patients
[32, 33] (and own data from clinic), and probably also in
a large part of synovial ﬂuid samples from RA patients,
interfereswithMIAcytokineconcentrationmeasurementsof



















































Figure 1: Measured concentrations in PEG 6000-precipitated and in nonprecipitated samples at diﬀerent spiked concentrations of IL-1β for
plasma (a) and synovial ﬂuid (b).
In general, the interference is likely to result in a higher
artefact value than the true one. However, we do see only
a minor eﬀect on the cytokine immunoassay in a plasma
sample with a very high RF concentration. This may be
causedbyRFbindingtoitself[4]duetothehighdistribution
ofRFinthisparticularsample,oritmaysimplybeduetothe
fact that only about 50% of RF is precipitated out, leaving
an RF concentration of two to three times what is usually
considered a high RF.
Interference of RF with the capture antibodies used in
immunoassays could be eliminated by truncating the Fc-
portion of them, but such modiﬁed capture antibodies for
the range of cytokines we wanted to determine are not avail-
able on the market at present. The seen interference of RF in
MIA can to a high degree be abolished by precipitation with
PEG 6000. This is in accordance with earlier observations
by De Jager’s group [24]. The chosen precipitation method
and concentration of PEG 6000 have the advantage of being
gentle to the analytes in question, showing no precipitation
of the cytokines when abolishing a high percentage of the RF.
Since RF is a mixture of autoantibodies [1, 3, 4], one must
conclude that following precipitation the remaining part of
RF must be mainly the monomeric less reactive types [3, 4]
which cause less interference than the precipitated part, since
spiking with cytokine prior to precipitation shows the same
cytokine concentration as spiking following precipitation.
This is in accordance with ﬁndings of Digeon et al. [28].
The interference of RF could be an ampliﬁed eﬀect in MIA,
although it is more likely to be an eﬀect of RF, especially
caused by the IgM part’s polyvalence [10]. Our results
c l e a r l ys u p p o r tt h i si d e a ,s i n c ew ed on o ts e ea n ys i g n i ﬁ c a n t
diﬀerence between singleplex and multiplex measurements.
One may ask if the amount of IgG1 detection antibody for
the particular cytokine would aﬀect the inﬂuence of presence
of RF on the measurements. For the cytokines in question
in this study, there is a diﬀerence between amount of the
diﬀerent IgG1s in the assay, but there is no diﬀerence in
interference seen which indicates that the setups are properly
optimized. This is further conﬁrmed by our recovery which
is in the same range of the manufacturers’. The recovery
d o e st h o u g hv a r yt os o m ee x t e n tw i t hc o n c e n t r a t i o n ,a n d
interference at the lower concentrations will therefore give
a larger problem. Overall, with PEG 6000 precipitation and a
further standard correction for interference of HAMAs with
addition of mouse serum and foetal bovine serum, a reliable
andsensitive assayforcytokine measurementsofRAsamples
is therefore at hand. When measuring the cytokines in SF,
the interference of RF was seen to be neglectable. This is
probably due to the high concentration of hyaluronic acid in
SF. Hyaluronic acid is shown to initiate formation of IgG-
IgM RF complexes [34] and may in this way abolish the
interference.
5. Conclusion
In conclusion, we recommend PEG 6000 precipitation of all
plasma from RA patients aimed at immunometric cytokine
determination like MIA and ELISA to avoid interference
from RF which otherwise may give apparently higher
cytokineconcentrationsthanthetrueone.PEGprecipitation
does not aﬀect the cytokines present in plasma.
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